Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine

The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after...

Full description

Bibliographic Details
Main Authors: Auchara Tangsathapornpong, Sira Nanthapisal, Kanassanan Pontan, Pornumpa Bunjoungmanee, Yamonbhorn Neamkul, Arthit Boonyarangkul, Supattra Wanpen, Waraphon Fukpho, Sumana Jitpokasem, Phuntila Tharabenjasin, Peera Jaru-Ampornpan
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Vaccines
Subjects:
COVID-19 vaccine
CoronaVac
AZD1222
mRNA-1273
booster dose
anti-SARS-CoV-2 IgG
Online Access:https://www.mdpi.com/2076-393X/11/3/553

Internet

https://www.mdpi.com/2076-393X/11/3/553

Similar Items